RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

The problem I see is that in the short term, we're close to being back in the same trap we thought we had gotten out of: assuming good trial results and/or IND approval, by the time it comes in late summer/early fall, corx will have operating funds for under a year. Share-price is going to be about where it is now, since concern about liquidity is going to cap any substantial upward movement.

The only hope here is more than one interested party for SA and/or ADHD. Otherwise, once again counterparties will wait to get the most favorable terms. In this regime, corx is once again going to have to raise funds.

If Samyang is the institution that provides the funds, this might not be too bad. In light of this, I think that an important indicator of corx's future prospects is whether or not Samyang opts for shares rather than cash. If they opt for shares, it will suggest that they maintain interest in the IP and the company, and thus perhaps would consider a second financing. If they choose cash, corx's prospects would appear dimmer.

Everything I've written assumes pretty smooth sailing. Bad trial results and/or slippage, and/or problems with the FDA will make this bad situation considerably worse.

I think we're in for more pain and waiting here.